# Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors

> **NCT02028507** · PHASE3 · COMPLETED · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 693 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Capecitabine
- **DRUG:** Exemestane
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT02028507
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-13
- **Primary completion:** 2019-01-14
- **Final completion:** 2021-01-11
- **Target enrollment:** 693 (ACTUAL)
- **Last updated:** 2024-09-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02028507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02028507, "Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02028507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*